Protagonist Therapeutics
PTGX
PTGX
144 hedge funds and large institutions have $946M invested in Protagonist Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 40 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
40% less capital invested
Capital invested by funds: $1.57B → $946M (-$621M)
56% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 39
Holders
144
Holding in Top 10
4
Calls
$12.2M
Puts
$1.14M
Top Buyers
| 1 | +$32.8M | |
| 2 | +$18.5M | |
| 3 | +$18.5M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.6M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14.1M |
Top Sellers
| 1 | -$41.4M | |
| 2 | -$22.2M | |
| 3 | -$13.8M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.2M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$11.8M |